Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › Natera Terminates Bio-Reference Labs NIPT Distribution Agreement

Natera Terminates Bio-Reference Labs NIPT Distribution Agreement

Jan 10, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Natera said today that it is ending its distribution agreement with Bio-Reference Laboratories, and plans instead to promote its Panorama noninvasive prenatal test and Horizon carrier screening test directly to clinicians.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

  2. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

  3. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  4. FDA Proposes Reclassification of Cytomegalovirus Quantitative Tests

  5. New York City Opening Dedicated COVID-19 Testing Laboratory

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.